Freenome, Inc FRNM
- Market cap
- $1.7B
- P/E
- 0.0×
Follow FRNM
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | 10.02 | 10.15 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | 10.22 | 13.95 |
High Price
|
|||
| — | — | — | — | — | — | — | — | — | — | Employees | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Emp | |||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | 2 | 1 |
EBT
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | — | — | — | — | — | — | 2 | 1 |
Net Income
|
|||
| — | — | — | — | — | — | — | — | — | — | Depreciation | |||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | — | 0.85 | 0.34 |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.16) | (0.35) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.16) | (0.35) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.94) | (1.96) |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | — | 2 | 2 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | 0 | (1) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | — | 0 | (1) |
FCF
|
|||
| — | — | — | — | — | — | — | — | 1 | (1) |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | (1) | (1) |
Net Debt
|
|||
| — | — | — | — | — | — | — | — | (2) | (5) |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.92% |
ROA
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.00% |
ROIC
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (24.23%) |
ROE
|
|||
Freenome, Inc peers in Shell Companies
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| IQMX IQM Quantum Computers Oyj | $2.0B | — | Compare |
| SECZ Securitize Corp. | $2.9B | 472× | Compare |
| BXBL BOXABL, Inc | $980.9M | 0.0× | Compare |
| LION Lionsgate Studios Corp. | $3.3B | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| LGV Longview Acquisition Corp. II | $870.3M | 6.4× | Compare |
| AVAN Avanti Acquisition Corp. | $753.0M | 3.4× | Compare |
| XXI Twenty One Capital, Inc. | $4.3B | 0.0× | Compare |
| EVAC EQV Ventures Acquisition Corp. II | $602.0M | 6.9× | Compare |
Freenome, Inc (FRNM) key facts
- Freenome, Inc (FRNM) is a Shell Companies company in the Financial sector, listed on Nasdaq.
- Net income was $837,500.00, or $0.34 per share (basic), a net margin of 0.00%.
- As of September 25, 2026, FRNM traded at $15.99, a market capitalization of $1.7 billion.
- Return on equity was −24.2% and debt-to-equity 0.00.
Freenome, Inc (FRNM) Latest News
12 Aug
FDA grants Breakthrough Device Designation to Freenome’s SimpleScreen™ blood-based test for lung cancer screening. Breakthrough device designation accelerates regulatory review and boosts Freenome’s competitive position in cancer diagnostics.
20 Jul
Perceptive Capital Solutions Corp. completes merger taking Freenome public as company focused on blood-based early cancer detection. Merger directly transforms PCSC into publicly traded vehicle for Freenome's cancer detection platform with major valuation impact.
9 Jul
Perceptive Capital Solutions Corp. SPAC merger with cancer blood screen firm delayed after test results. Merger delay triggered by test results directly threatens PCSC's core transaction and investor outlook.
18 Jun
Perceptive Capital Solutions Corp and Freenome announced effectiveness of the registration statement for their proposed business combination. Effectiveness of the registration statement advances the business combination with Freenome, positioning PCSC for substantial strategic transformation.
5 Dec
Freenome and Perceptive Capital Solutions Corp. (PCSC) have entered into a business combination agreement aimed at creating a publicly listed company focused on transforming blood-based multi-cancer detection through an AI/ML-enabled multiomics platform. This strategic move is expected to enhance the capabilities of cancer detection and diagnostics, leveraging advanced technology to improve patient outcomes. The business combination is likely to significantly impact future performance by introducing innovative cancer detection technologies and enhancing market positioning.
Perceptive Capital Solutions Corp. (PCSC) has emerged as one of the top midday gainers in the market, reflecting a notable increase in its stock price. This surge is attributed to positive investor sentiment and potential growth prospects, positioning PCSC favorably among its peers. Analysts are closely monitoring the company's performance as it continues to attract attention from investors. The stock's midday gain indicates a moderately noticeable influence on market sentiment and potential financial performance.
12 Jun
Perceptive Capital Solutions Corp priced its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share, focusing on healthcare industry in the US and other developed countries. The pricing of the IPO and focus on healthcare industry are significant strategic moves that could alter the company's trajectory and investor sentiment.